Pemetrexed Export Market Intelligence: India's 138 Suppliers Shipping to 92 Countries — TransData Nexus 2026

Q: Who are the top pemetrexed exporters from India?

The top pemetrexed exporters from India are: 1. FRESENIUS KABI ONCOLOGY LIMITED — $9.0M (31.1% market share); 2. EUGIA PHARMA SPECIALITIES LIMITED — $7.0M (24.4% market share); 3. JODAS EXPOIM PRIVATE LIMITED — $2.5M (8.7% market share); 4. SUN PHARMACEUTICAL INDUSTRIES LIMITED — $2.0M (7.0% market share); 5. RELIANCE LIFE SCIENCES PRIVATE LIMITED — $2.0M (6.9% market share). Together they account for 78.1% of India's total pemetrexed export value.

Q: What is the total export value of pemetrexed from India?

The total export value of pemetrexed from India is $28.8M USD, recorded across 1,209 shipment transactions from 138 active exporters to 92 destination countries. The average shipment value is $23.9K.

Q: Which countries import pemetrexed from India?

India exports pemetrexed to 92 countries worldwide. The top importing countries are: GERMANY (30.1% share, $8.7M), UNITED STATES (26.8% share, $7.7M), RUSSIA (9.0% share, $2.6M), POLAND (5.6% share, $1.6M), CANADA (5.2% share, $1.5M). These five markets account for 76.8% of total export value.

Q: What is the HS code for pemetrexed exports from India?

The primary HS code for pemetrexed exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of pemetrexed exports from India?

The average unit price for pemetrexed exports from India is $27.92 USD per unit, with prices ranging from $0.04 to $1494.40 depending on formulation, packaging, and order volume. The total market is valued at $28.8M across 1,209 shipments.

Q: Which ports handle pemetrexed exports from India?

The primary ports for pemetrexed exports from India are DELHI AIR CARGO ACC (INDEL4) (17.3% of shipments), SAHAR AIR CARGO ACC (INBOM4) (15.0% of shipments), SAHAR AIR (13.5% of shipments), DELHI AIR (11.0% of shipments), CHAWAPAYAL ICD (3.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of pemetrexed?

India is one of the world's leading exporters of pemetrexed due to its large base of 138 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports pemetrexed to 92 countries, demonstrating 47% global market coverage.

Q: What certifications do Indian pemetrexed exporters need?

Indian pemetrexed exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import pemetrexed from India?

There are 309 registered buyers importing pemetrexed from India, spread across 92 countries. The repeat buyer rate is 53.1%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top pemetrexed supplier from India?

FRESENIUS KABI ONCOLOGY LIMITED is the leading pemetrexed exporter from India with a market share of 31.1% and total export value of $9.0M across 333 shipments. The top 5 suppliers together control 78.1% of total export value.

Suresh Sormare

Pemetrexed

India Pharmaceutical Trade Intelligence

$28.8M138 Suppliers92 CountriesHS 30049049

ExportsIndia → GERMANY30.1%India → UNITED STATES26.8%

ImportsFRANCE → India$36.6M SOUTH KOREA → India$147.9K

#1 Supplier: FRESENIUS KABI #1 Buyer: FRESENIUS KABI

Pemetrexed Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Pemetrexed to the World

Between 2022 and 2026, India exported $28.8M worth of pemetrexed across 1,209 verified shipments to 92 countries — covering 47% of world markets in the Advanced Oncology segment. The largest destination is GERMANY (30.1%). FRESENIUS KABI ONCOLOGY LIMITED leads with a 31.1% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Pemetrexed export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Pemetrexed export data snapshot — $28.8M · 138 exporters · 92 countriesTransData Nexus · Indian Customs Data

Top Pemetrexed Exporters from India

138 active exporters · Ranked by export value

View all 138 →

Top Pemetrexed Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	FRESENIUS KABI ONCOLOGY LIMITED	$9.0M	333	5	31.1%
2	EUGIA PHARMA SPECIALITIES LIMITED

Top Countries Importing Pemetrexed from India

92 destination markets · Ranked by import value

All 92 countries →

Top Countries Importing Pemetrexed from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	GERMANY	$8.7M	30.1%
2	UNITED STATES	$7.7M	26.8%
3	RUSSIA	$2.6M	9.0%
4	POLAND	$1.6M	5.6%
5	CANADA	$1.5M	5.2%
6	BELGIUM	$1.3M	4.4%
7	VIETNAM	$900.3K	3.1%
8	PHILIPPINES	$608.2K	2.1%
9	AUSTRALIA	$566.5K	2.0%
10	MOROCCO	$549.1K	1.9%

GERMANY is India's largest pemetrexed export destination, absorbing 30.1% of total exports worth $8.7M. The top 5 importing countries — GERMANY, UNITED STATES, RUSSIA, POLAND, CANADA — together account for 76.8% of India's total pemetrexed export value. The remaining 87 destination countries collectively receive the other 23.2%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Pemetrexed to India?

15 origin countries · Total import value: $37.0M

India imports pemetrexed from 15 countries with a combined import value of $37.0M. The largest supplier is FRANCE ($36.6M, 8 shipments), followed by SOUTH KOREA and UNITED STATES. All values are from Indian Customs (DGFT) import records.

Countries Supplying Pemetrexed to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	FRANCE	$36.6M	8	99.1%
2	SOUTH KOREA	$147.9K	5	0.4%
3	UNITED STATES	$42.7K	8	0.1%
4	BELGIUM	$26.7K	16	0.1%
5	UNITED KINGDOM	$24.9K	5	0.1%
6	UNITED ARAB EMIRATES	$17.8K	1	0.0%
7	CANADA	$16.4K	4	0.0%
8	NETHERLANDS	$16.4K	3	0.0%
9	SOUTH AFRICA	$14.4K	2	0.0%
10	CHINA	$11.4K	9	0.0%

Showing top 10 of 15 origin countries

FRANCE is the largest supplier of pemetrexed to India, accounting for 99.1% of total import value. The top 5 origin countries — FRANCE, SOUTH KOREA, UNITED STATES, BELGIUM, UNITED KINGDOM — together supply 99.7% of India's pemetrexed imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Pemetrexed

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, Pemetrexed is approved for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Pemetrexed, indicating a competitive generic market. Notably, Fresenius Kabi Oncology Limited, the leading Indian exporter with a 31.1% share, has an approved ANDA for Pemetrexed, facilitating its substantial export volume to the U.S.

The regulatory pathway for Pemetrexed in the U.S. involves demonstrating bioequivalence to the reference listed drug, Alimta. As of March 2026, there are no active FDA import alerts specifically targeting Pemetrexed from India, suggesting compliance with U.S. regulatory standards. The presence of 138 active Indian exporters underscores the robust participation of Indian manufacturers in the U.S. market.

2EU & UK Regulatory Framework

In the European Union, Pemetrexed is authorized for similar oncological indications. The European Medicines Agency (EMA) has approved several generic versions, including Pemetrexed Accord, which received marketing authorization on 18 January 2016. However, some marketing authorizations have been withdrawn; for instance, Pemetrexed Sandoz's authorization was withdrawn on 9 October 2024 at the request of the marketing authorization holder for commercial reasons. (ema.europa.eu)

The United Kingdom, post-Brexit, continues to align closely with EMA standards through the Medicines and Healthcare products Regulatory Agency (MHRA). EU Good Manufacturing Practice (GMP) requirements are stringent, necessitating compliance from Indian exporters to ensure market access. The significant export volumes to Germany (30.1%) and Poland (5.6%) reflect adherence to these regulatory standards.

3WHO Essential Medicines & Global Standards

Pemetrexed is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in cancer treatment. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality benchmarks across different markets.

4India Regulatory Classification

In India, Pemetrexed is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing under the Drug Price Control Order (DPCO). As of March 2026, the ceiling price for Pemetrexed is set at ₹2,500 per 500 mg vial, effective from January 2026. For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

5Patent & Exclusivity Status

The primary patent for Pemetrexed expired in December 2015, leading to increased generic competition globally. This expiration has facilitated the entry of multiple Indian manufacturers into international markets, as evidenced by the 138 active exporters and the average Free on Board (FOB) unit price of $27.92.

6Recent Industry Developments

In June 2025, the NPPA revised the ceiling price for Pemetrexed, reducing it by 10% to ₹2,500 per 500 mg vial, effective from January 2026, to enhance affordability.

In September 2025, the EMA withdrew the marketing authorization for Pemetrexed Krka at the request of the marketing authorization holder, citing commercial reasons. (ema.europa.eu)

In November 2025, the FDA approved a new generic version of Pemetrexed by an Indian manufacturer, further intensifying market competition.

In January 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Pemetrexed, highlighting its continued significance in global cancer treatment protocols.

In February 2026, the CDSCO issued a directive mandating stricter compliance with GMP standards for Pemetrexed manufacturers, aiming to bolster the quality of exports.

These developments reflect the dynamic regulatory landscape surrounding Pemetrexed, influencing both domestic and international market dynamics.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Supply Chain Risk Assessment — Pemetrexed

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Pemetrexed, an antineoplastic agent, relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) predominantly sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This heavy reliance on Chinese KSMs introduces significant supply chain vulnerabilities, as disruptions in China's production or export activities can directly impact the availability of Pemetrexed APIs.

Recent geopolitical tensions and trade disputes have exacerbated these risks. For instance, in 2022, China's stringent COVID-19 lockdowns temporarily halted approximately 30% of intermediate exports, including those critical for Pemetrexed production. Such disruptions underscore the fragility of the supply chain and the potential for significant delays in Pemetrexed manufacturing.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five Indian exporters account for 78.1% of Pemetrexed exports, with FRESENIUS KABI ONCOLOGY LIMITED alone contributing 31.1%. This high supplier concentration poses a substantial risk, as any operational or regulatory issues affecting these key players could disrupt the global supply of Pemetrexed.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. By 2025, 48 projects had been approved under the scheme, with significant capacity created for fermentation-based products like Penicillin G, which India had ceased producing decades ago. While this initiative is a positive step, its impact on reducing dependency on Chinese KSMs for Pemetrexed remains to be fully realized.

Access Complete Pemetrexed Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,209 transactions across 92 markets.

Request Demo View Pricing

Frequently Asked Questions — Pemetrexed Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top pemetrexed exporters from India?

The leading pemetrexed exporters from India are FRESENIUS KABI ONCOLOGY LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, JODAS EXPOIM PRIVATE LIMITED, and 12 others. FRESENIUS KABI ONCOLOGY LIMITED leads with 31.1% market share ($9.0M). The top 5 suppliers together control 78.1% of total export value.

What is the total export value of pemetrexed from India?

The total export value of pemetrexed from India is $28.8M, recorded across 1,209 shipments from 138 active exporters to 92 countries. The average shipment value is $23.9K.

Which countries import pemetrexed from India?

India exports pemetrexed to 92 countries. The top importing countries are GERMANY (30.1%), UNITED STATES (26.8%), RUSSIA (9.0%), POLAND (5.6%), CANADA (5.2%), which together account for 76.8% of total export value.

What is the HS code for pemetrexed exports from India?

The primary HS code for pemetrexed exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Pemetrexed

Pemetrexed

How India Exports Pemetrexed to the World

Top Pemetrexed Exporters from India

Top Countries Importing Pemetrexed from India

Who Supplies Pemetrexed to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Pemetrexed

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Pemetrexed

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Pemetrexed Trade Intelligence

Frequently Asked Questions — Pemetrexed Exports from India

Who are the top pemetrexed exporters from India?

What is the total export value of pemetrexed from India?

Which countries import pemetrexed from India?

What is the HS code for pemetrexed exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of pemetrexed exports from India?

Which ports handle pemetrexed exports from India?

Why is India a leading exporter of pemetrexed?

What certifications do Indian pemetrexed exporters need?

How many buyers import pemetrexed from India?

What is the market share of the top pemetrexed exporter from India?

Analysis Methodology